Pancreatic Cancer Research

ResearcherUniversity of AntwerpActive in the last 2 years

Geert Roeyen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2947-1407; OpenAlex author ID A5064708716. Sources: ClinicalTrials.gov.

Their work

Papers
21 (first author 1, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
80
Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: none · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 3 papers · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 5 papers · 2026: 5 papers

Papers 21

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. Protein-level profiling of TIGIT axis components in human PDAC reveals immune-suppressive expression patterns. Co-author DOI 10.1007/s00262-026-04343-w↗
  3. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2026.117352↗
  4. IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting. Co-author DOI 10.1016/j.omton.2026.201316↗
  5. International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot. Co-author DOI 10.1016/j.suronc.2026.102580↗
  6. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  7. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  8. Stereotactic body radiation therapy for inoperable non-metastasized pancreatic adenocarcinoma: a randomised phase II study (TORPEDO). Co-author DOI 10.1186/s12885-025-15041-8↗
  9. Capturing the Heterogeneity of the PDAC Tumor Microenvironment: Novel Triple Co-Culture Spheroids for Drug Screening and Angiogenic Evaluation. Co-author DOI 10.3390/cells14060450↗
  10. Use of Irreversible Electroporation in Pancreatic Cancer Patients: A Multi-Center Experience. Co-author DOI 10.3390/curroncol32100574↗
  11. Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by… Co-author DOI 10.1186/s13046-024-03012-z↗
  12. Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. Co-author DOI 10.1038/s41698-023-00480-y↗
  13. Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer. Co-author DOI 10.1016/j.esmoop.2022.100386↗
  14. Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pharmthera.2022.108107↗
  15. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled… Co-author DOI 10.1186/s13063-021-05248-y↗
  16. Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Co-author DOI 10.3390/cancers13050987↗
  17. Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment. Co-author DOI 10.1002/cti2.1165↗
  18. Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review. First author DOI 10.1016/j.pharmthera.2018.04.003↗
  19. Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6391-z↗
  20. Correction to: Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6442-5↗
  21. Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Co-author DOI 10.18632/oncotarget.18185↗

Trials 1

  1. Reduced Pancreatic Fistula Rate Following Pancreaticoduodenectomy: Trial on Pancreaticogastrostomy Versus Pancreaticojejunostomy Principal investigator NCT00830778↗

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Evelien Smits · 9 shared papers, 2017–2026 · strength 1.29
  2. Marc Peeters · 9 shared papers, 2017–2026 · strength 1.25
  3. Jonas R.M. Van Audenaerde · 8 shared papers, 2017–2026 · strength 1.20
  4. Hans Prenen · 6 shared papers, 2021–2026 · strength 1.05
  5. Christophe Deben · 5 shared papers, 2021–2026 · strength 0.89
  6. Delphine Quatannens · 5 shared papers, 2020–2026 · strength 0.83
  7. Frederik Christiaan Berrevoet · 4 shared papers, 2018–2025 · strength 0.51
  8. Timon Vandamme · 3 shared papers, 2021–2025 · strength 0.45
  9. Maxim Le Compte · 2 shared papers, 2023–2024 · strength 0.33
  10. Andreas Domen · 2 shared papers, 2021–2023 · strength 0.26
  11. Bart Hendrikx · 1 shared paper, 2025 · strength 0.25
  12. Filip Gryspeerdt · 1 shared paper, 2025 · strength 0.25
  13. Ruben Verloy · 1 shared paper, 2025 · strength 0.23
  14. Angela Privat‐Maldonado · 1 shared paper, 2025 · strength 0.23
  15. Annemie Bogaerts · 1 shared paper, 2025 · strength 0.23
  16. Laura Gehrcken · 1 shared paper, 2026 · strength 0.22
  17. Daan Stas · 1 shared paper, 2025 · strength 0.19
  18. Ines Joye · 1 shared paper, 2025 · strength 0.19
  19. Christelle Bouchart · 1 shared paper, 2025 · strength 0.19
  20. Baki Topal · 1 shared paper, 1 shared trial, 2009–2022 · strength 0.19
  21. Marc G. Besselink · 3 shared papers, 2018–2021 · strength 0.18
  22. Jean‐Luc Van Laethem · 1 shared paper, 2022 · strength 0.16
  23. Karen Paula Geboes · 1 shared paper, 2022 · strength 0.16
  24. Eric Van Cutsem · 1 shared paper, 2022 · strength 0.16
  25. Jinthe Van Loenhout · 2 shared papers, 2017–2020 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.